{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:58:53Z","timestamp":1790999933935,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":589,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100015334","name":"Endocrine Fellows Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["DE-000758-01"],"award-info":[{"award-number":["DE-000758-01"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015334","name":"Endocrine Fellows Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["DE\u2010000758\u201001"],"award-info":[{"award-number":["DE\u2010000758\u201001"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Fibrous dysplasia (FD) is a rare mosaic disorder resulting in fractures, pain, and disability. Bone lesions appear during childhood and expand during skeletal growth. The rate at which FD lesions progress and the biochemical determinants of FD lesion formation have not been established, making it difficult to investigate and implement preventative therapies. The purpose of this study was to characterize FD lesion progression in children, and to identify clinical variables associated with progressive disease. Clinical data and imaging from an ongoing natural history study at the National Institutes of Health (NIH) were reviewed. 99m-Technetium methylene diphosphonate (99Tc-MDP) scans were used to determine Skeletal Burden Score (SBS), a validated quantitative scoring system. FD progression rate was determined by the change in the SBS in each patient per year. Thirty-one children had serial 99Tc-MDP scans, with a median age at first scan of 6\u2009years (interquartile range [IQR] 4\u20138, range 2\u201310), and median follow-up 1.1\u2009years (IQR 1.1\u20132.1, range 0.7\u201311.2). The median FD progression rate for the total group was 2.12 SBS units\/year (IQR 0.81\u20132.94, range 0.05\u20137.81). FD progression rates were highest in children under age 8\u2009years and declined with age (p\u00a0=\u00a00.03). Baseline disease severity was associated with subsequent disease progression (p\u00a0=\u00a00.009), with the highest FD progression rates in patients with moderate disease (baseline SBS 16\u201330), and lowest progression rates in those with severe disease (SBS \u226550). Serum levels of the bone formation marker osteocalcin were positively correlated with subsequent FD progression rate (p\u00a0=\u00a00.01, R\u00a0=\u00a00.58). There was no association between FD progression and baseline endocrinopathies, fractures, or surgery rates. FD lesions progress during childhood, particularly in younger children and those with moderate involvement. Osteocalcin may potentially serve as a biomarker for progressive disease. These findings may allow clinicians to investigate preventative therapies, and to identify children with FD who are candidates for early interventions. Published 2022. This article is a U.S. Government work and is in the public domain in the USA.<\/jats:p>","DOI":"10.1002\/jbmr.4618","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T08:18:40Z","timestamp":1655108320000},"page":"1473-1478","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Skeletal Disease Acquisition in Fibrous Dysplasia: Natural History and Indicators of Lesion Progression in Children"],"prefix":"10.1093","volume":"37","author":[{"given":"Vivian","family":"Szymczuk","sequence":"first","affiliation":[{"name":"Pediatric Endocrinology Inter-Institute Training Program National Institute of Child Health and Development, National Institutes of Health Bethesda MD USA"},{"name":"Metabolic Bone Disorders Unit National Institute of Dental and Craniofacial Research, National Institutes of Health Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Taylor","sequence":"additional","affiliation":[{"name":"Metabolic Bone Disorders Unit National Institute of Dental and Craniofacial Research, National Institutes of Health Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Michel","sequence":"additional","affiliation":[{"name":"Skeletal Disorders and Mineral Homeostasis Section National Institute of Dental and Craniofacial Research, National Institutes of Health Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninet","family":"Sinaii","sequence":"additional","affiliation":[{"name":"Biostatistics and Clinical Epidemiology Service Clinical Center, National Institutes of Health Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2987-3887","authenticated-orcid":false,"given":"Alison M.","family":"Boyce","sequence":"additional","affiliation":[{"name":"Metabolic Bone Disorders Unit National Institute of Dental and Craniofacial Research, National Institutes of Health Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"2","key":"2024012713552557800_jbmr4618-bib-0001","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/endrev\/bnz011","article-title":"Fibrous dysplasia\/McCune-Albright syndrome: a rare, mosaic disease of G\u03b1\u200as activation","volume":"41","author":"Boyce","year":"2020","journal-title":"Endocr Rev"},{"issue":"9","key":"2024012713552557800_jbmr4618-bib-0002","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1359\/jbmr.070511","article-title":"Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome","volume":"22","author":"Hart","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024012713552557800_jbmr4618-bib-0003","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J","article-title":"The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks","volume":"187","author":"Riminucci","year":"1999","journal-title":"J Pathol"},{"issue":"2","key":"2024012713552557800_jbmr4618-bib-0004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1359\/JBMR.041111","article-title":"An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone","volume":"20","author":"Collins","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024012713552557800_jbmr4618-bib-0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/jbmr.3602","article-title":"Activation of RANK\/RANKL\/OPG pathway is involved in the pathophysiology of fibrous dysplasia and associated with disease burden","volume":"34","author":"de Castro","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024012713552557800_jbmr4618-bib-0006","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2024012713552557800_jbmr4618-bib-0007","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1210\/jc.2018-02543","article-title":"Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates","volume":"104","author":"Majoor","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024012713552557800_jbmr4618-bib-0008","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/jbmr.3828","article-title":"RANKL inhibition in fibrous dysplasia of bone: a preclinical study in a mouse model of the human disease","volume":"34","author":"Palmisano","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024012713552557800_jbmr4618-bib-0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2024012713552557800_jbmr4618-bib-0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/cen.13722","article-title":"Growth hormone-insulin-like growth factor 1 axis hyperactivity on bone fibrous dysplasia in McCune-Albright syndrome","volume":"89","author":"Tessaris","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2024012713552557800_jbmr4618-bib-0011","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1210\/jc.2016-3693","article-title":"Calcium and bone turnover markers in acromegaly: a prospective, controlled study","volume":"102","author":"Constantin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024012713552557800_jbmr4618-bib-0012","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jbmr.4463","article-title":"Long bone fractures in fibrous dysplasia\/McCune-Albright syndrome: prevalence, natural history, and risk factors","volume":"37","author":"Geels","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2024012713552557800_jbmr4618-bib-0013","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0046-8177(99)90162-4","article-title":"A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to expressions of c-fos and c-jun products and bone matrix proteins: a clinicopathologic review and immunohistochemical study of c-fos, c-jun, type I collagen, osteonectin, osteopontin, and osteocalcin","volume":"30","author":"Sakamoto","year":"1999","journal-title":"Hum Pathol"},{"issue":"5","key":"2024012713552557800_jbmr4618-bib-0014","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.tripleo.2010.06.014","article-title":"Markers of bone remodeling in neoplastic and bone-related lesions","volume":"110","author":"Elias","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"9","key":"2024012713552557800_jbmr4618-bib-0015","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/jbmr.3738","article-title":"(18) F-NaF PET\/CT Imaging in fibrous dysplasia of bone","volume":"34","author":"Papadakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024012713552557800_jbmr4618-bib-0016","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jbmr.3446","article-title":"Scoliosis in fibrous dysplasia\/McCune-Albright syndrome: factors associated with curve progression and effects of bisphosphonates","volume":"33","author":"Berglund","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024012713552557800_jbmr4618-bib-0017","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00198-021-05895-6","article-title":"Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects","volume":"32","author":"Raborn","year":"2021","journal-title":"Osteoporos Int"},{"issue":"2","key":"2024012713552557800_jbmr4618-bib-0018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11914-021-00657-z","article-title":"Denosumab treatment for giant cell tumors, aneurysmal bone cysts, and fibrous dysplasia-risks and benefits","volume":"19","author":"Pan","year":"2021","journal-title":"Curr Osteoporos Rep"},{"key":"2024012713552557800_jbmr4618-bib-0019","article-title":"A GTP-state specific cyclic peptide inhibitor of the GTPase G\u03b1s","author":"Dai","year":"2020","journal-title":"bioRxiv"},{"issue":"4","key":"2024012713552557800_jbmr4618-bib-0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jbmr.3649","article-title":"Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone","volume":"34","author":"Florenzano","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024012713552557800_jbmr4618-bib-0021","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2014-1371","article-title":"A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone","volume":"99","author":"Boyce","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4618","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4618","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/37\/8\/1473\/55455835\/jbmr4618.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/37\/8\/1473\/55455835\/jbmr4618.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:09:15Z","timestamp":1710328155000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/37\/8\/1473-1478\/7516578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,6,13]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4618","relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JBMR.4618\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4618\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4618\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4618\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4618\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4618\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4618\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2022-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}